Eton Pharmaceuticals

Eton Pharmaceuticals Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

Our newest product, Desmoda™ (desmopressin acetate), was featured on the NASDAQ MarketSite board in Times Square. Seeing...
03/10/2026

Our newest product, Desmoda™ (desmopressin acetate), was featured on the NASDAQ MarketSite board in Times Square.

Seeing Desmoda highlighted in such an iconic place is a meaningful milestone and a reminder of the work that goes into bringing new treatments to patients.

Behind every approval is a tremendous amount of work, collaboration, and belief in the patients we aim to serve. Moments like this are an opportunity to pause and appreciate the progress.

Thank you to everyone who contributed to making this achievement possible.

To learn more about Desmoda please visit: https://desmoda.com

Please see full package insert:https://www.etonpharma.com/wp-content/uploads/2026/02/Combined-Promo-Label-1.pdf

Last week, we celebrated on Capitol Hill, hosted by the Rare Disease Legislative Advocates, a program of the EveryLife...
03/06/2026

Last week, we celebrated on Capitol Hill, hosted by the Rare Disease Legislative Advocates, a program of the EveryLife Foundation for Rare Diseases and at Boston Children’s Hospital.

We also had the incredible opportunity to engage with the liver and rare disease communities at the Liver Connect Conference , hosted by the Chronic Liver Disease Foundation.

These events highlight that advancing care for rare diseases relies on collaboration. Patients, families, clinicians, researchers, and advocates each bring unique perspectives, and true progress happens when we unite our efforts.

A heartfelt thank you to the organizers and everyone who made these events possible!

We are proud to announce that Eton Pharmaceuticals has expanded its rare disease portfolio through the acquisition of U....
03/02/2026

We are proud to announce that Eton Pharmaceuticals has expanded its rare disease portfolio through the acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution.

Please read the full press release here: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-expands-rare-disease-portfolio-through

This milestone represents continued progress in advancing our mission to support patients, families, and healthcare providers in rare disease communities.

Today is Rare Disease Day.For those living with a rare condition, this isn’t just a date on the calendar. It’s a level o...
02/28/2026

Today is Rare Disease Day.

For those living with a rare condition, this isn’t just a date on the calendar. It’s a level of resilience most people never see.

At Eton, we have the privilege of working in rare disease every day. We see the dedication of healthcare providers, the strength of families, and the determination of patients who refuse to be defined by a diagnosis.

We’re proud to do our part to expand treatment options and support the communities we serve. The work matters because the people behind it matter.

We’re proud to share that the U.S. FDA has approved Desmoda™ (desmopressin acetate) oral solution, the latest addition t...
02/25/2026

We’re proud to share that the U.S. FDA has approved Desmoda™ (desmopressin acetate) oral solution, the latest addition to Eton Pharmaceuticals’ growing product portfolio.

Read the full press release: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-desmodatm

Bringing Desmoda™ to approval required collaboration, persistence, and a strong belief that underserved patient communities deserve meaningful therapeutic options. Today’s approval reinforces our commitment to advancing treatments where the need is greatest.

To the patients who inspire our mission every day, this is why we do what we do.
To the Eton team and our partners who made this possible, thank you.

Please see full package insert:https://www.etonpharma.com/wp-content/uploads/2026/02/Combined-Promo-Label-1.pdf

Last week, the Eton team came together in Southern California for our 2026 National Sales Meeting, Beyond the Break: Mas...
01/29/2026

Last week, the Eton team came together in Southern California for our 2026 National Sales Meeting, Beyond the Break: Mastery in Motion.

It was a powerful few days of strategy, learning, recognition, and real connection. We aligned on what’s ahead, sharpened our skills, and celebrated the people who make our work matter every day. From thoughtful discussions to team energy you could feel in the room, this meeting was a reminder of what’s possible when focus, momentum, and purpose come together.

We also recognized colleagues who delivered outstanding results last year, celebrating the dedication and excellence that move our business.

Grateful for this team and the commitment they bring to serving rare disease communities. Beyond the break, together.

Wishing you a meaningful Thanksgiving from the Eton team.This time of year reminds us why we do what we do. We’re gratef...
11/26/2025

Wishing you a meaningful Thanksgiving from the Eton team.

This time of year reminds us why we do what we do. We’re grateful for the rare disease communities who share their experiences with us, the healthcare professionals who push for answers, and the partners who help move important work forward. Your dedication shapes every decision we make.

We’re thankful for the opportunity to support patients who rely on us and for the continued trust placed in our therapies and our team. It’s a responsibility we take to heart.

We hope your holiday is filled with good food, good company, and a moment to slow down and enjoy it all.

Happy Thanksgiving. 🦃🍁

We were proud to attend the Raymond A. Wood Foundation Pituitary Brain Tumor Family Conference in Philadelphia on Novemb...
11/26/2025

We were proud to attend the Raymond A. Wood Foundation Pituitary Brain Tumor Family Conference in Philadelphia on November 15 and 16.

The foundation is a parent and patient-led rare disease patient advocacy organization.

Their mission is to empower survivors of craniopharyngioma and hypothalamic-pituitary brain tumors with an improved quality of life by providing access to education, technology, and evolving treatments.

We valued the opportunity to meet patients and their families, listen to their stories, and learn about their journeys.

We had a great experience at , The American Association for the Study of Liver Diseases (AASLD) "The Liver Meeting 2025...
11/26/2025

We had a great experience at , The American Association for the Study of Liver Diseases (AASLD) "The Liver Meeting 2025".

The AASLD is the leading organization for advancing liver disease research, education, and clinical practice, bringing together experts dedicated to improving patient care.

It was a meaningful opportunity to connect with clinicians, researchers, and partners who are shaping the future of liver care.

Our team appreciated the thoughtful discussions, the insights shared throughout the meeting, and the chance to engage with so many dedicated liver disease professionals, including clinicians, researchers, and partners who are shaping the future of liver care.

Thank you to everyone who took the time to meet with us. We’re grateful for the conversations and look forward to building on the momentum from this year’s meeting.

Eton Pharmaceuticals was honored to participate in the Wilson Disease Association 2025 Conference in Sacramento, Califor...
11/26/2025

Eton Pharmaceuticals was honored to participate in the Wilson Disease Association 2025 Conference in Sacramento, California, led by Rhonda Rowland and the dedicated WDA team. The event brought together patients, caregivers, clinicians, and researchers who share a common goal: improving the lives of those affected by .

We’re proud to support the WDA’s mission through ongoing education, advocacy, and collaboration. Connecting directly with this inspiring community reminds us why we are and fuels our commitment to delivering meaningful therapies and comprehensive patient support through .

A special highlight of the weekend was the launch of the WDA’s Copper Conscious Cookbook, available on Amazon beginning December 6 on .

A heartfelt thank you to the WDA board members, team, and all participants for the important work you do each day to advance awareness, diagnosis, and treatment for Wilson disease.

We’re heading to Denver! Eton Pharmaceuticals is proud to attend the American Academy of Pediatrics (AAP) 2025 National ...
09/25/2025

We’re heading to Denver! Eton Pharmaceuticals is proud to attend the American Academy of Pediatrics (AAP) 2025 National Conference & Exhibition from September 26–30.

Stop by Booth #453 to meet our team, learn more about our commitment to reimagining rare medicines, and explore how we support pediatric patients and their families.

We look forward to connecting with healthcare professionals, advocates, and partners dedicated to advancing pediatric care. See you in Denver!

This week, we raise awareness of childhood growth disorders.MAGIC’s motto says it best: Children have a short time to gr...
09/16/2025

This week, we raise awareness of childhood growth disorders.

MAGIC’s motto says it best: Children have a short time to grow and a lifetime to live with the results. Help us raise awareness and share this message.

magicfoundation.org

Address

21925 W Field Pkwy #235
Deer Park, IL
60010

Website

Alerts

Be the first to know and let us send you an email when Eton Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Eton Pharmaceuticals:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category